Ricardo Parrondo

1.4k total citations
75 papers, 698 citations indexed

About

Ricardo Parrondo is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Ricardo Parrondo has authored 75 papers receiving a total of 698 indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Hematology, 29 papers in Molecular Biology and 27 papers in Oncology. Recurrent topics in Ricardo Parrondo's work include Multiple Myeloma Research and Treatments (35 papers), Chronic Lymphocytic Leukemia Research (19 papers) and Protein Degradation and Inhibitors (15 papers). Ricardo Parrondo is often cited by papers focused on Multiple Myeloma Research and Treatments (35 papers), Chronic Lymphocytic Leukemia Research (19 papers) and Protein Degradation and Inhibitors (15 papers). Ricardo Parrondo collaborates with scholars based in United States, Italy and Australia. Ricardo Parrondo's co-authors include Carlos Perez‐Stable, Alicia de las Pozas, Teresita Reiner, Taimur Sher, Sikander Ailawadhi, Priyamvada Rai, Vivek Roy, Asher Chanan‐Khan, Miriam Redrado and Irene Manrique and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Ricardo Parrondo

65 papers receiving 692 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ricardo Parrondo United States	15	374	255	196	130	102	75	698
Celine Pitou United States	14	347 0.9×	289 1.1×	82 0.4×	113 0.9×	68 0.7×	24	641
Sharon Friedlander United States	10	437 1.2×	333 1.3×	146 0.7×	76 0.6×	67 0.7×	35	748
Betty Glinsmann‐Gibson United States	15	422 1.1×	272 1.1×	409 2.1×	146 1.1×	105 1.0×	23	853
Maria Stella Pennisi Italy	14	294 0.8×	187 0.7×	283 1.4×	235 1.8×	91 0.9×	34	798
Rosalind H. Gunby Italy	13	316 0.8×	180 0.7×	267 1.4×	222 1.7×	85 0.8×	17	683
Masamichi Mori Japan	17	524 1.4×	407 1.6×	249 1.3×	131 1.0×	93 0.9×	41	1.1k
Donald P. Lesslie United States	8	397 1.1×	353 1.4×	96 0.5×	58 0.4×	71 0.7×	11	687
Natalia Liem Singapore	14	566 1.5×	302 1.2×	168 0.9×	48 0.4×	97 1.0×	18	944
Zhihong Zeng United States	6	467 1.2×	111 0.4×	203 1.0×	119 0.9×	114 1.1×	13	652
Xiaosheng Fang China	15	300 0.8×	196 0.8×	57 0.3×	99 0.8×	176 1.7×	69	661

Countries citing papers authored by Ricardo Parrondo

Since Specialization

Citations

This map shows the geographic impact of Ricardo Parrondo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ricardo Parrondo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ricardo Parrondo more than expected).

Fields of papers citing papers by Ricardo Parrondo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ricardo Parrondo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ricardo Parrondo. The network helps show where Ricardo Parrondo may publish in the future.

Co-authorship network of co-authors of Ricardo Parrondo

This figure shows the co-authorship network connecting the top 25 collaborators of Ricardo Parrondo. A scholar is included among the top collaborators of Ricardo Parrondo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ricardo Parrondo. Ricardo Parrondo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mian, Hira, Thomas G Martin, Gregory R. Pond, et al.. (2025). Outcomes of frailty subgroups of older adults (age ≥ 70) treated with teclistamab: an International Myeloma Foundation immunotherapy database real-world analysis. Leukemia. 39(5). 1252–1255. 1 indexed citations

Chhabra, Saurabh, Ricardo Parrondo, Morie A. Gertz, et al.. (2025). Risk Factors for Immune Effector Cell-Associated Enterocolitis (IEC-colitis) in Patients with Relapsed Myeloma Treated with Ciltacabtagene Autoleucel (cilta-cel). Transplantation and Cellular Therapy. 31(2). S234–S235. 1 indexed citations

Parrondo, Ricardo, Saurabh Chhabra, Morie A. Gertz, et al.. (2025). Investigating the association between peak post-infusion absolute lymphocyte count (ALC) and delayed toxicity in myeloma (MM) patients (pts) receiving cilta-cel.. Journal of Clinical Oncology. 43(16_suppl). 7522–7522. 2 indexed citations

Ailawadhi, Sikander, Ryan D. Frank, David O. Hodge, et al.. (2024). Factors determining utilization of stem cell transplant for initial therapy of multiple myeloma by patient race: exploring intra-racial healthcare disparities. Blood Cancer Journal. 14(1). 86–86. 5 indexed citations

Thompson, Meghan C., Ricardo Parrondo, Anna Maria Frustaci, et al.. (2024). Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results from the Phase 1 CaDAnCe-101 Study. Blood. 144(Supplement 1). 885–885. 14 indexed citations

Parrondo, Ricardo, Sikander Ailawadhi, & Claudio Cerchione. (2024). Bispecific antibodies for the treatment of relapsed/refractory multiple myeloma: updates and future perspectives. Frontiers in Oncology. 14. 1394048–1394048. 3 indexed citations

Parrondo, Ricardo, et al.. (2023). Patient Awareness of CAR-T and Bispecific Antibody Treatments for Multiple Myeloma: Real-World Learnings and Disparities. Blood. 142(Supplement 1). 2418–2418. 2 indexed citations

Charalampous, Charalampos, Shaji Kumar, Ricardo Parrondo, et al.. (2023). Patient-Reported Outcomes Among Patients with Triple-Class Refractory Multiple Myeloma in Real-World Clinical Practice: A Prospective, Multi-Site Observational Study. Blood. 142(Supplement 1). 6727–6727.

Mohty, Razan, Martha E. Gadd, Yan Luo, et al.. (2023). Chimeric Antigen Receptor T-cell Therapy for Chronic Lymphocytic Leukemia: What is the supporting evidence so far?. PubMed. 5(4). 33–46. 2 indexed citations

10.

Ailawadhi, Sikander, Ricardo Parrondo, Vivek Roy, et al.. (2023). The digital divide: Racial disparities in adoption and utilization of health information technology among patients with lymphoid cancers. Cancer Medicine. 12(18). 19013–19020. 2 indexed citations

11.

Popat, Rakesh, Joaquín Martínez‐López, Efstathios Kastritis, et al.. (2023). Real-World Evaluation of Teclistamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM). Blood. 142(Supplement 1). 3347–3347. 7 indexed citations

12.

Moustafa, Muhamad Alhaj, Ricardo Parrondo, Vivek Roy, et al.. (2023). Daratumumab-lenalidomide and daratumumab-pomalidomide in relapsed lenalidomide-exposed or refractory multiple myeloma. Anti-Cancer Drugs. 35(1). 63–69. 1 indexed citations

13.

Parrondo, Ricardo, et al.. (2022). Neuropsychiatric Manifestations of Lymphoma-Associated Cerebral Glucose Hypometabolism Can Be Reversed by Intensive Glucose Supplementation. SHILAP Revista de lepidopterología.

14.

Parrondo, Ricardo, Aneel Paulus, & Sikander Ailawadhi. (2022). Updates in the Use of BCL-2-Family Small Molecule Inhibitors for the Treatment of Relapsed/Refractory Multiple Myeloma. Cancers. 14(14). 3330–3330. 8 indexed citations

15.

Rahman, Zaid Abdel, Ricardo Parrondo, Michael G. Heckman, et al.. (2021). Comparative study of therapy‐related and de novo adult b‐cell acute lymphoblastic leukaemia. British Journal of Haematology. 196(4). 963–968. 7 indexed citations

16.

Jiang, Liuyan, Victoria R. Alegria, Taimur Sher, et al.. (2021). Management of lytic bone disease in lymphoplasmacytic lymphoma: A case report and review of the literature. SHILAP Revista de lepidopterología. 9(12). e05181–e05181. 2 indexed citations

17.

Kharfan‐Dabaja, Mohamed A., et al.. (2020). Primary diffuse large B‐cell lymphoma presenting as acute appendicitis: A report of 2 cases and a literature review. SHILAP Revista de lepidopterología. 8(2). 293–298. 4 indexed citations

18.

Sokol, Ethan, Lee A. Albacker, Aixa Soyano, et al.. (2019). Abstract 4894: Incidence of high tumor mutation burden (TMB) and PD-L1 positivity in breast cancers and potential response to immune checkpoint inhibitors (ICPIs). Cancer Research. 79(13_Supplement). 4894–4894. 3 indexed citations

19.

Ailawadhi, Sikander, Victoria R. Alegria, Salman Ahmed, et al.. (2019). Phase I Study of a Novel Bcl-2 Inhibitor, at-101 in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM). Blood. 134(Supplement_1). 3137–3137. 4 indexed citations

20.

Rios, Carmen I., Gianluca D’Ippolito, Kevin M. Curtis, et al.. (2016). Low Oxygen Modulates Multiple Signaling Pathways, Increasing Self-Renewal, While Decreasing Differentiation, Senescence, and Apoptosis in Stromal MIAMI Cells. Stem Cells and Development. 25(11). 848–860. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact